Home › Funds › Integral Health Asset Management, LLC › SYRE
Integral Health Asset Management, LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
Integral Health Asset Management, LLC reported holding 325,000 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$28.9M, representing 1.30% of its reported portfolio and ranking #25 among its reported holdings. Integral Health Asset Management, LLC has disclosed SYRE holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Integral Health Asset Management, LLC's SYRE position evolved
Integral Health Asset Management, LLC first disclosed a stake in SYRE in Q1 2024 at 100,000 shares (US$3.8M). The position peaked in Q2 2026 at 325,000 shares, worth US$28.9M. Across 3 filings, Integral Health Asset Management, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 325,000 shares valued at US$28.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 100.00K | $3.79M | New |
| Q2 2024 | 100.00K | $2.35M | Hold |
| Q2 2026 | 325.00K | $28.85M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M sh · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.46M sh · $129.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.56M · Q2 2026
- Siren, L.L.C. 968.60K sh · $85.99M · Q2 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
More on Integral Health Asset Management, LLC
FAQ
How long has Integral Health Asset Management, LLC held SYRE?
Integral Health Asset Management, LLC has disclosed SYRE holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
What is Integral Health Asset Management, LLC's current position in SYRE?
As of Q2 2026, Integral Health Asset Management, LLC holds 325.00K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $28.85M, representing 1.30% of its reported portfolio and ranking #25.
Has Integral Health Asset Management, LLC been buying or selling SYRE?
In the latest 13F filing (Q2 2026), Integral Health Asset Management, LLC newly opened its position in SYRE. The position peaked in Q2 2026 at 325.00K shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.